semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Parkinson's Disease A diagnosis of idiopathic Parkinson's disease, with bilateral symptoms at Hoehn and Yahr Stage greater than or equal to II Documented improvement in motor signs on versus off dopaminergic medication, with a change in the Unified Parkinson's Disease Rating Scale motor (UPDRS III) score of >= 30% off to on medication The presence of complications of medication such as wearing off signs, fluctuating responses and/or dyskinesias, and/or medication refractory tremor, and/or impairment in the quality of life on or off medication due to these factors Subjects should be on stable doses of medications, which should remain unchanged until the DBS system is activated. After the DBS system is optimized (during which time the overall medication dose may be reduced to avoid discomfort and complications such as dyskinesias) the medication dose should remain unchanged, if possible, for the duration of the study Treatment with carbidopa/levodopa, and with a dopamine agonist at the maximal tolerated doses as determined by a movement disorders neurologist Age > 18  Subjects with significant cognitive impairment and/or dementia as determined by a standardized neuropsychological battery Subjects with clinically active depression, defined according to the Diagnostic and Statistical manual of Mental Disorders, Fourth Edition (DSM-IV) and as scored on a validated depression assessment scale Subjects with very advanced Parkinson's disease, Hoehn and Yahr stage 5 on medication (non-ambulatory) Age > 80 Subjects with an implanted electronic device such as a neurostimulator, cardiac pacemaker/defibrillator or medication pump Subjects, who are pregnant, are capable of becoming pregnant, or who are breast feeding Patients with cortical atrophy out of proportion to age or focal brain lesions that could indicate a non-idiopathic movement disorder as determined by MRI Subjects having a major comorbidity increasing the risk of surgery (prior stroke, severe hypertension, severe diabetes, or need for chronic anticoagulation other than aspirin) Subjects having any prior intracranial surgery Subjects with a history of seizures
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  REM Sleep Behavior Disorder Subject was enrolled voluntarily and understood the contents of this clinical trial Subject was diagnosed as Parkinson disease (PD) or Parkinson's syndrome Hoehn and Yahr (H&Y) stage 1, 2, or 3 Existence of caregivers who can provide a information about symptoms of rapid eye movement sleep disorder (RBD) of the participant Existence of RBD by answering "yes" to the question (RBD-1Q): "Have you ever been told, or suspected yourself, that you seem to 'act out your dreams' while asleep (for example, punching, flailing your arms in the air, making running movements, etc.)?"  Existence of cognitive decline hard to participate in the clinical trial Subject has confusion or visual hallucination in daytime Diagnosed as obstructive sleep apnea or severe snoring Previous clonazepam treatment within 4 weeks Current treatment with benzodiazepines at bedtime Alcoholics or drug abuser Lactating, pregnant, or possible pregnant Hypersensitivity to clonazepam or benzodiazepines Prior participation to other clinical trials within 3 months Presence of severe comorbidities or a cancer
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Alcohol Dependence Experienced binge drinking episode(s) (5 or more standard drinks for men and 4 or more standard drinks for women consumed in about 2 hours according to NIAAA definition) in the past 30 days  DSM-IV diagnosed alcohol dependence, other drug dependencies including nicotine dependence
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 7.0-17.0,  Cerebral Palsy Children with spastic Cerebral Palsy (CP) Ages 7 (inclusive) GMFCS I-II (Gross Motor Function Classification System) Diplegia, Hemiplegia Balance problems identified (Determined by primary PT's treating problem list and/or score on balance assessments in use) Parental Informed Consent Can follow verbal instructions and willing to participate in a group intervention setting  Recent surgery to lower limbs (within past year) Botulinum Toxin (BTX-A) or serial casting to lower limbs within the last 3 months (or planned for during intervention or control period) Completed a core stability training group within the previous year Neurological or orthopaedic conditions unrelated to CP Behavioural difficulties limiting ability to participate in groups Intellectual difficulty that would make it difficult to comprehend and cooperate with treatment and/or testing
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson's Disease Diagnosis of idiopathic Parkinson's disease Has Deep Brain Stimulation Implant for Parkinson's disease Historical bradykinesia rating of 2 or greater on at least one of the Unified Parkinson's Disease Rating Scale (UPDRS) finger-tapping, hand-movements, and pronation-supination tasks with DBS off  Dementia (MoCA < 25)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Parkinson's Disease • Adults ≥ 18 years old Patients with Parkinson's disease diagnosed according to the with predominantly feature of rest tremor that intractable to medically treatment Informed consent  Patients with a history of cardiac arrhythmia, renal failure, hepatic failure, and pregnancy as well as those who had history of seizure or had the risk for tended to become seizure such as those who had focal brain lesions, encephalitis, and stroke patients Patients with a history of hand surgery and implanted screws or wires in hand area that supposed to place a surface EMG or EMS, as well as those patients who were implanted for electrical devices such as cardiac pacemaker, pulse generator of deep brain stimulation,and intrathecal baclofen pump Patients who cannot avoid the medication that may potentiate or attenuate tremor such as antihistamines, benzodiazepine, illicit drugs, and thyroid hormone supplement
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Idiopathic Parkinson Disease L-DOPA-responsiveness Hoehn & Yahr Stage II-III inclusive Experiencing motor fluctuations Stable daily dose of L-DOPA of at least 300 mg Females on non-childbearing potential and male subjects  History of troublesome dyskinesias History of surgical intervention for Parkinson's disease
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Hepatic Encephalopathy Patients aged between 18 and 65 years of either gender Patients admitted to the hospital with liver cirrhosis and grade 3 or grade 4 (West Haven Criteria) HE Patients treated with lactulose retention enema within 48 hours of onset of grade 3 or 4 (West Haven Criteria) HE  Patients treated with agents other than lactulose retention enema for grade 3 or 4 (West Haven Criteria) HE Patients who had significant concomitant diseases that could impair or contribute to the impairment of consciousness Patients who had a major neuropsychiatric illness Patients who had a contraindication to lactulose, including Hypersensitivity to the active substance or to any of the ingredients; Galactosaemia; Gastrointestinal obstruction, digestive perforation or risk of digestive perforation
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Parkinson Disease for Parkinson disease (PD) subjects with freezing of gait (FOG) Diagnosis of PD by United Kingdom Brain bank Hoehn & Yahr stage I-IV Levodopa treated and responsive Able to manage 12 hours off dopaminergic medication Age 18-85 years Presence of FOG by history and seen by examiner at their clinical office visit or in a video taken at home Able sign a consent document and willing to participate in all aspects of the study Able to have an MRI scan (no pacemakers or history of claustrophobia)  for Parkinson disease (PD) subjects with freezing of gait (FOG) Dementia that precludes completing study protocol Stage V PD unable to walk independently when "off" History of FOG without ever being seen to have it Atypical parkinsonism: Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD), Vascular Parkinsonism Treatment with medications that cause parkinsonism: drug-induced parkinsonism Any neurological or orthopedic disorders that interfere with gait Treatment with medications that will interfere with NET-PET (norepinephrine transporter-positron emission tomography) ligand binding a. Noradrenergic drugs: methylphenidate, atomoxetine, serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine) Absence or loss of levodopa response
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 45.0-70.0,  Parkinson's Disease Idiopathic PD 2. Gait and locomotion problems as the main complain/symptom 3. PD patients with or without DBS 4. Hoehn and Yahr scale equal or more than 2.0  Dementia 2. Hoehn and Yahr scale more than 4 3. Less than 5 years of Parkinson's disease symptoms 4. General contraindications of surgery
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Stroke individuals wich hemiparesis stemming from a stroke Rating of Functional Mobility Scale levels (FMS functional mobility scale) Walking at least 50 meters (GRAHAN et al. 2004); Science signature in consent term exempt and enlightened (TCLE)   Positive Cutoff to cognitive wastage screening (mental mini) Visual commitment may intervene in tests achievement Cardiac vast problems and use of pacemaker Contraindication of tDCS application (history of recurrent seizures, recurrent epilepsy and brain tumor in stimulation site)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Crohn Disease Colitis, Ulcerative Intestinal Helminthiasis The included volunteer is a researcher within parasitology with main focus on Trichuris trichiura and Trichiura suis. He planned to infect himself and contacted our department with the purpose of being monitored during this infection for safety (medical supervision) and research reasons. The only clinical criterion for his in the study was that he was healthy  N/A
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Parkinson Disease more or equal than 18 years old and less than 70 years patient affiliated to social security or similarly regime informed consent form signed parkinson disease (UPDRS III20 score up than 30/108 except for severe tremors) motor and non motor dysfunctions pre-operative cerebral MRI without lesion without chirurgical contraindications without psychiatric disease  Pregnant women and lactating mothers Ward of court or under guardianship Adult unable to express their consent Person deprived of freedom by judicial or administrative decision Person hospitalized without their consent Person under legal protection Person with carcinological antecedent during precedent 5 years Chirurgical or MRI contraindications
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Parkinson's Disease Patients diagnosed as Parkinson's disease according to Queen Brain Bank Patients who have been diagnosed as dementia after diagnosing Parkinson's disease at least 1 year Patients with Hoehn and Yahr staging from 2 to 4 Patients with MMSE score from 10 to 24 Patients who have taken donepezil for at least 12 weeks before screening period Patients whose medications for Parkinson's disease have not change for 1 month Patients who give informed consent  Patients who cannot be performed neuropsychiatric test because of hearing and visual difficulty Patients who have taken medicine affecting cognitive function such as anticholinergic drug and memantine -Patients diagnosed as dementia with Lewy body and vascular dementia- Patients who have history of neurosyphilis, head trauma, encephalitis or other movement disorders Patients who have psychiatric disease Except patients who are stable state under antidepressant or atypical neuroleptics Patients with child-bearing periods Patients who have severe liver or kidney disease necessary for aggressive treatment Patients who have gastrointestinal disease needed for treatment Patients who cannot taken tablet per oral Patients who are participated in other clinical trial except observational study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Mandibular Hypoplasia patients were diagnosed by computed tomography CT, cone beam each of them had from two to four compromised teeth  patients who did not return for review after six months